Veracyte

Traded on the St. Petersburg Stock Exchange
Veracyte is a genomic diagnostics company.
Veracyte stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Veracyte balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Veracyte cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Veracyte multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Veracyte profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Veracyte assets
Veracyte cash flows

Veracyte shares

TickerNameTypeNominal valueISINPrice
VCYT:USVeracyte, Inc.Common share-US92337F1075$21.09
Veracyte news
04.05.2022
The loss of Veracyte under GAAP for the 3 months of 2022 was $14.461 million, down 2.9 times from $41.868 million in the previous year. Revenue increased 84.7% to $67.783 million from $36.703 million a year earlier.
Source: {source} pictogram investor.veracyte.com
Pictogram next
01.03.2022
Veracyte's GAAP loss for 2021 was $75.563 million, up 2.2 times from $34.909 million in the previous year. Revenue increased 86.8% to $219.514 million from $117.483 million a year earlier.
Source: {source} pictogram investor.veracyte.com
Pictogram next
10.11.2021
Veracyte's GAAP loss for 9M 2021 was $65.035 million, up 2.4 times from $26.865 million in the previous year. Revenue increased 83.5% to $152.178 million from $82.947 million a year earlier.
Source: {source} pictogram investor.veracyte.com
Pictogram next
30.07.2021
Veracyte's GAAP loss for the six months of 2021 was $50.906 million, up 2.2 times from $22.741 million in the previous year. Revenue increased 77.1% to $91.808 million from $51.826 million a year earlier.
Source: {source} pictogram investor.veracyte.com
Pictogram next
All Veracyte news
General information
Company nameVeracyte
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 243-6300
Mailing address6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Websitewww.veracyte.com
Information disclosurewww.sec.gov